Bengaluru, 23 October, 2024 Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as ...

Indian multinational pharmaceutical company Zydus Lifesciences Ltd on Wednesday announced that its Typhoid Vi conjugate ...

Dr Ayobami Alabi, a consultant paediatrician at the Ladoke Akintola University of Technology Teaching Hospital, says in this interview with SADE OGUNTOLA, ...

Zydus Lifesciences Ltd has received in-principle approval from the WHO for its Typhoid Vi conjugate vaccine, ZyVac TCV.

As per GAVI (2022) it is estimated that Typhoid accounts for an estimated 11 to 21 million cases of febrile illness and ...

Zydus Lifesciences' shares rose 2.81% after receiving WHO approval for its indigenously developed typhoid vaccine, ZyVac TCV, ...

Ahmedabad: Zydus Lifesciences Limited has announced that it has received in principle acceptability from World Health ...

Zydus Lifesciences advanced 1.71% to Rs 1,005.05 after the company received in principle acceptability from World Health Organisation (WHO) for its ZyVac TCV vaccine.

A new report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year ...

But do we really know what causes it? The culprit behind this illness is Salmonella enterica serovar Typhi, a bacterium that might seem common, but can be deadly. Another related bacterium ...